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Abstract: Sudden cardiac death, or SCD, results from the heart failing to pump blood to 
the rest of the body.1  Sudden cardiac death, the leading cause of natural death in the 
United States, and is caused from a variety of factors including diet, lifestyle, and 
genetics.  This research focuses on the underlying genetic cause(s) of heart failure leading 
to SCD.  There are hundreds of genes that can affect cardiac function and to study them 
all represents an enormous task.  Therefore, this study concentrated on a handful of genes 
suspected to be associated with defects in cardiac function and possibly SCD.  The genes 
studied included: EYA4, TNNI3, MYH6, and NEXN.  These genes chosen were based 
upon the scientific literature and also on some preliminary studies performed in the lab 
using next generation sequencing on a sample of DNA obtained from a child who died 
from no known cause and was highly suspected of being an SCD victim.  Within these 
genes, five single nucleotide polymorphisms (SNPs) were identified as candidates for 
research.  SNaPshotTM is a method that allows of several steps that ultimately allow the 
nucleotide at a particular position within a DNA sequence to be identified.  Thus, rather 
than producing a continuous sequence of nucleotides in a DNA fragment, SNaPshotTM 
technology allows the nucleotide at one specific position within a DNA fragment to be 
identified.  Using this method, the five SNPs were evaluated to see if the nucleotide in the 
SNP site was mutated or wildtype.  Two groups of individuals (one defined as “normal” 
or from individuals of older age with no known heart history and the other as “medical 
examiner samples” or samples from individuals who passed away from a cardiac 
incident) were tested to determine if there was any correlation between the SNP 
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 On July 27, 1993, at an off-season practice a 27-year-old Boston Celtics player 
collapsed on the court.  After several attempts of resuscitation, Reggie Lewis was 
pronounced dead due to heart failure.  The sudden death sparked public awareness of the 
devastating finality of sudden cardiac death.  Sudden cardiac death, or SCD, is an 
umbrella term for the unforeseen loss of life caused by a sudden stop in heart function.  
Lewis’s death opened the eyes of the public to the fact that SCD is not just an effect of 
not eating properly or exercising enough but could be caused by nucleotide sequence 
variations in someone’s genome involving genes associated with cardiac function.  
Unfortunately, many different genetic defects can result in the heterogenetic condition of 
SCD that makes diagnostic screening for SCD difficult at best.  Understanding the 
consequences of the large number of genetic variations that exist in genes associated with 
cardiac function is unclear and considerable research will have to be performed to 
identify the constellation of variants that, individually or in combination, lead to elevated 
risk for SCD.  With enough time and effort, the genes that cause sudden cardiac death can 
be identified and put to diagnostic use in a clinical setting.  Once a diagnostic protocol is 
developed, screening for the pathogenic nucleotides in genomic DNA can be performed
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 and early death from SCD can be reduced.  In this study, a gene panel of 4 genes 
exhibiting 5 single nucleotide variations was sequenced to explore the correlation of these 
variations with cardiac function defects that could be related to death.   
Sudden cardiac death defined, in the broadest sense, is an unexpected death that is 
caused by a sudden loss of cardiac function.1  However, SCD is not a heart attack.  
Sudden cardiac death occurs when the electrical system of the heart is not working 
properly and causes irregular heartbeats.  The irregularity in beating dangerously reduces 
the oxygen in the body, which can cause severe brain damage if not regulated.  In 
contrast, heart attacks damage hearts when there is a defect in the coronary arteries.  The 
defect prevents the heart from obtaining the oxygenated blood, and many people can 
survive the episodes.  In both situations, the brain not having access to oxygen is a main 
concern.  Emergency treatment can sometimes save the SCD victim’s life, but the 
treatment is needed immediately to help chances of survival.  Actions that can help save a 
victim of SCD are cardiopulmonary resuscitation, or CPR, and defibrillation.  CPR helps 
by pushing oxygen in the lungs to the brain to maintain brain function until the heart is 
back to its normal rhythm, and the defibrillation helps to push the heart back into its 
normal contraction rhythm.1 
In the United States of America, sudden cardiac death accounts for half of all 
heart disease deaths, killing around 325,000 adults each year.1  The number of deaths 
attributed to SCD each year makes it the largest cause of natural death in the USA.  
Adults in their mid-30s are most likely to be affected by SCD, and sudden cardiac death 
appears twice as often in men compared to women. Sudden cardiac deaths are usually 
caused by arrhythmias, which are abnormal heart rhythms.2  Arrhythmias can be caused 
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by any number of conditions such as coronary artery disease, electrolyte imbalances in 
blood (diet), heart muscle changes, and genetics.  Underlying genetic causes of sudden 
cardiac death were the focus of this research.  
 Genetic causation of sudden cardiac death can stem from a single mutation that 
eliminates the critical functioning of a gene essential for cardiac function.  However, the 
literature suggests that the less that optimal functioning of the products of a constellation 
of genes associated with cardiac function is the more likely cause of SCD.  Single 
nucleotide polymorphisms, or SNPs, are nucleotide variations that change a DNA 
sequence and, when they occur in genes, SNPs can alter the amino acid sequence of a 
gene product (changing the amino acid) or even silence a gene altogether.  SNPs are the 
most common type of nucleotide sequence variation in the human genome and can be 
detected through DNA sequencing, RFLP mapping, or other molecular methods.   
The study of SCD has involved the use of massively parallel DNA sequencing 
(MPS) techniques3, also known as next generation DNA sequencing because the method 
allows one to identify variations in a large cohort of genes that may be associated with a 
particular physiological function in a single molecular assay.  While this approach may 
be time and cost effective to produce large amounts of sequence data, managing and 
interpreting the data within the context of a particular disease state is not straightforward, 
not to mention the costs associated with generating the data to begin with.  Selective gene 
panels offer an alternative to whole genome or exome sequencing.  Gene panels look at a 
limited number of genes instead of the whole genome or exome and can vary in number 
from a few to hundreds of genes depending on how correlated defects in the genes chosen 
are to a disease state.   
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When working with known SNPs in a limited number of genes associated with a 
particular condition, a number of molecular techniques can be used to characterize the 
nucleotide resident at the SNP site.  This study used a method known as SNaPshotTM 
(Thermo Fisher Scientific, Waltham, MA) to specifically identify the nucleotides residing 
at 5 SNP sites located in 4 genes known to be involved in cardiac muscle structure and in 
the normal functioning of the heart.  These SNPs therefore constituted the gene panel for 
the study.  The SNaPshotTM method uses oligonucleotide primers that hybridize to 
genomic DNA template one nucleotide upstream from a SNP site.  Once hybridized, the 
primer can be extended through the SNP site through the action of DNA polymerase 
adding a di-deoxynucleotide that is complementary to the template.  If the ddNTP 
incorporated is coupled to one of 4 different fluorescent dyes, the color of the 
incorporated ddNDP will identify the nucleotide resident in the SNP.  
Samples from 2 different population groups were obtained for this research: a 
collection of post mortem samples provided by the Office of the Chief Medical 
Examiner, Eastern Office, Tulsa, OK that were collected from cardiac incident victims 
and a group of samples from heart healthy, aged 40 or above, living individuals provided 
by the Oklahoma State University Human Identity Testing Laboratory.  These 2 types of 
samples were tested with the chosen panel of 5 SNPs in the 4 different genes: EYA4, 
EYA4-2, MYH6, TNNI3, and NEXN.  Nucleotides resident at these SNP sites have been 
identified in the literature as either “wild type” or “pathogenic” depending upon the 
nucleotide at the site and their associations with heart function.3,4  Our goal was to 
determine SNP genotypes in a cohort of young decedents subjected to autopsy by the 
Office of the Chief Medical Examiner and found either to have died from cardiac 
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incidents or to be candidates for SCD.  The incidence of pathogenic SNPs in this group 
was then compared with the incidence of pathogenic SNPs in the cohort of presumably 
normal controls. 
Sudden cardiac death can be a deadly consequence of genetic mutations that occur 
in genes associated with heart function.  Unfortunately, the rather large amount of natural 
genetic variation in the human genome often complicates research aimed at an 
understanding of multi-genic conditions such as SCD.  The research performed here aims 
to determine whether there is any amount of correlation between the nucleotides residing 
at the five SNP sites in the four genes studied and cardiac related deaths.  Understanding 
such associations will be the key to identify elevated risk through genetic testing and 





REVIEW OF LITERATURE 
 
Sudden cardiac death, or SCD, results from the heart failing to pump blood to the 
rest of the body.  A SCD incident is different from a heart attack, however.  A heart 
attack, which occurs while the individual is fully conscious, is more of a stutter in the 
heartbeat (which can cause a heart to stop) while a sudden cardiac attack makes the 
person lose consciousness and the heart stops beating altogether.1  Sudden cardiac death 
is the leading cause of natural death in the United States and is caused by a variety of 
factors including diet, lifestyle, and genetics.  The research presented here focuses on the 
underlying genetic cause(s) of heart failure. 
Technological advances that allow researchers to examine either small or large 
percentages of the human genome economically and in a timely fashion have led to an 
increase in studies devoted to the association of gene defects with sudden cardiac death.  
Due to the sudden deaths in young athletes being reported more and more frequently, 
notoriety for SCD has also increased.  
There are hundreds of genes that can affect cardiac function and to study them all 
would requires considerable expense; interpreting the extensive genetic data produced is 
complicated and often does not provide a compelling picture of the cause of an SCD 
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event, probably because of the coordinated failure of many genes that can contribute to 
the condition.  Therefore, for both expediency and to keep with budget constraints this 
study was narrowed down to 4 genes suspected of being associated with defects in 
cardiac function.  The 4 genes and their associated SNPs were chosen were based upon 
the literature and some preliminary studies performed here in the OSU Human Identify 
Testing laboratory using next generation sequencing on a sample of DNA obtained from 
a child who died from no known cause who was highly suspected of being an SCD 
victim.  This chapter will summarize the published literature connected with background 
information on SCD, current methodology used to analyze the genetics associated with 
SCD, selection of genes for SCD research, and the specific SNPs that were chosen for 
this research.  It is hoped our research will add to the body of knowledge surrounding the 
underlying genetic causes of SCD.  While causative associations of particular gene 
defects that are uncovered may not help the victim of SCD, such information would be of 
value to his or her family to take preventative measures to reduce the chance of SCD in 
other family members. 
Background Information on SCD 
 Sudden Cardiac Death Definition and Statistics 
 Sudden cardiac death is an umbrella term for the death of an individual as a result 
of an unexpected loss of cardiac function.1  SCD is caused when the electrical signaling 
in the cardiac muscles fails to work properly and causes irregularity in the beating of the 
heart.  Heartbeats can become either dangerously fast or dangerously slow, causing 
inappropriate amounts of blood to be delivered to the rest of the body.  Likewise, sudden 
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cardiac death can result from defects in heart muscle traceable to defects in genes 
encoding those proteins involved in contraction of the heart.  In both instances, a 
principal concern is that the brain will not receive sufficient oxygen due to the loss of 
blood flow.  If immediate action is not taken the loss of oxygen can cause the victim to 
lose consciousness and to suffer severe brain damage.  The disease can also be defined by 
the sudden loss of a pulse due to an abnormal heart beat rhythm with no known 
underlying cardiac cause.5  The definition of SCD is important in regards to research on 
SCD because either a loose or a strict definition will define the source of biological 
samples to be used for study on the underlying cause of SCD.  For example, if SCD is 
broadly defined, then patients used as a source of samples for research will be equally 
broad and studies could lead to erroneous conclusions regarding the pathology underlying 
SCD.  In contrast, if the definition is narrow, patient samples will be fewer and some 
underlying causes may be missed.   
A factor that sets SCD apart from other cardiac conditions is that victims 
suddenly lose consciousness due to the stoppage of the heart.  The sudden 
unconsciousness experienced by victims of SCD complicate delivering medical attention 
because unconsciousness may result from many other more benign causes, and the loss of 
cardiac function may not be recognized and treatment may not be begun quickly enough 
for survival.    
Most victims of sudden cardiac death are young; sometimes adults in their mid-
30s.  Men are twice as likely to be affected by SCD as women. Yearly, around 325 000 
adults die from this disease in the United States.1  This number can vary, however, 
depending upon how broad or narrow the definition of SCD.  The number of deaths in the 
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United States, using the broadest definition of SCD, is as high as 400,000 individuals.6  
Even with the strong advances in cardiac resuscitation, many people still do not survive a 
sudden cardiac incident.5  Although statistically uncommon in young individuals, sudden 
cardiac death causes from 1 to 10 deaths per 100,000 children (infant to 18-years-old) in 
America each year.7  A young person’s sudden cardiac death is often greatly publicized 
and receives considerable national attention.   
The most common cause for sudden cardiac death in people under the age of 35 
stems from ion channelopathies.8  Ion channels represent “gates” inside the heart tissue 
that regulate the flow of ions and other molecules into heart muscle cells and help 
regulate heartbeat.  Channelopathies occur when ion gates are not functioning properly 
and the heart rhythm is at risk of breaking down.  The suffix -opathy denotes a disorder.9  
Appearing often in young athletes, channelopathies and hard exercise can trigger the fatal 
cardiac episode due to the high demand for blood flow athletic exercise causes.8  
Cardiomyopathy, a disorder of the heart muscle structure, was reported in 35% of young 
athletes who have died in the United States.8  SCD can therefore result from both 
cardiomyopathies and ion channelopathies.  
Genetic Look at SCD 
 The traditional method of studying a disorder involving a genetic cause is to 
compare suspected defective genes in the patient and in family members as well.  In the 
case of SCD, affected individuals often do not know they carry a defect until it is too late.   
Scientific interest in SCD as a disease resulting from gene defects has grown over the 
past 12 years.10   Moreover, advances in our ability to identify defective genes involved 
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with cardiac function has advanced as well, enabling gene defects that could result in 
SCD to be detected before the death of the individual in question.  Using genetic testing 
to identify family members that may be at risk for a disease is known as family cascade 
testing.10  
One of the problems associated with uncovering genetic defects that elevate the 
risk of SCD is the large number of genes involved with proper cardiac function and the 
fact that individual genetic defects may not precipitate SCD.  Rather, defects in a number 
of genes, each individually not capable of causing SCD, can coordinately compromise 
cardiac function to the point that a high demand for blood flow during exercise for 
example results in SCD.8  Many people die from this disease without even knowing they 
are at risk because the effects of the gene variants do not reveal themselves during normal 
activity.  The more research that is done on the genetics of SCD, the more people can be 
warned and saved from an early death.   
The Genes Associated with SCD Related Cardiomyopathies  
 Cardiomyopathy is defined as a disease that affects the muscles of the heart.11  
While not always lethal, cardiomyopathies can have serious consequences for cardiac 
function and discomfort in victims with this condition.  There are 4 basic types of 
cardiomyopathy: dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), 
arrhythmogenic right ventricular cardiomyopathy (ARVC), and restrictive 
cardiomyopathy (RCM).  These 4 types of cardiomyopathies differ in many ways but 
lead to similar pathologic conditions; some cardiomyopathies can cause sudden cardiac 
death.   
11	  
	  
 Dilated cardiomyopathy, or DCM, causes heart chamber dilation and therefore 
poor contraction in the left (or sometimes both) ventricles of the heart.  DCM can be 
caused by a number of factors including myocarditis, alcohol abuse, metabolic disorders, 
autoimmune disease, familial factors, and genetic factors to name a few.11  The genes 
EYA4, MYH6, NEXN, and TNNI3 have all been associated with this type of 
cardiomyopathy as well (Table 1).3  
 Hypertrophic cardiomyopathy, or HCM, results when the left and/or right 
ventricles exhibit hypertrophy, or thickening of the heart muscle.11  HCM can cause 
arrhythmias and sudden death in individuals.  HCM is the most common cause of SCD in 
young adults under the age of 30.  HCM also is the cause for a high proportion of sudden 
deaths in athletes.  The main cause of hypertrophic cardiomyopathy is familial 
inheritance with an autosomal dominant inheritance pattern.  Autosomal dominant 
inheritance will be expressed in one generation to the next and will not skip generations.  
Although the disease does not skip generations, the expression in members may vary 
from severely affected to not so severely affected.11  In other words the penetrance of the 
gene defect can vary suggesting other, as yet unknown gene defects may also be involved 
in the disease pathology.  The genes MYH6, NEXN, and TNNI3 are all correlated with 
this myopathy (Table 1).3  
 Arrhythmogenic right ventricular cardiomyopathy, or ARVC, causes atrophy in 
the right ventricular muscle and gradually replaces the heart muscle with fatty tissue.11  
The replacement of heart muscle by fat can create bulges and weakness in the cardiac 
wall and eventually lead to heart failure.  ARVC can be found mostly in young adults but 
is also seen in older age groups.  ARVC can cause sudden cardiac death in young people 
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who would otherwise have a very sound heart.  ARVC, like HCM, is inherited in an 
autosomal dominant pattern.11  
 Restrictive cardiomyopathy, or RCM is the least common cardiomyopathy and 
causes impaired ventricular filling.11  RCM can result from increased stiffness in the 
myocardium (heart muscle) that creates pressure in the ventricle(s).  Sometimes RCM 
can be familial and inherited; in 30% of cases, there is a family history of 
cardiomyopathy.11 
 
Methods for Genetic Analysis: Next Generation DNA Sequencing (NGS) 
Identifying the mutations or pathogenic variations that lead to sudden cardiac 
death has become more feasible due to the massive parallel DNA sequencing (MPS) 
technology (also known as NGS) available today.  Using MPS, it is now possible to 
determine the nucleotide sequence of hundreds of genes in a single sequence analysis and 
to identify variations in the nucleotide sequence of DNA from SCD patients when 
compared against the same genes in a normal healthy individual.  These gene deviations 
may represent single nucleotide substitutions (SNPs), small insertions or deletions of 
nucleotides, or other variations not seen in a “normal” genome.  Several NGS platforms 
Table	  1.	  Sudden	  cardiac	  death	  related	  genes	  for	  current	  research.	  
Gene Name Chromosome DCM HCM 
EYA4 6 X  
MYH6 14 X X 
TNNI3 19 X X 




are available commercially at present and each has advantages and disadvantages over 
competitors.  
Ion Torrent 
One NGS platform that is used widely for sequencing to identify candidate 
mutations/variations responsible for cardiomyopathy is known as the Ion Torrent.4  The 
Ion Torrent uses ion semiconductor sequencing to determine the order of nucleotides in 
DNA molecules in a very cost effective way.  The technology behind the Ion Torrent 
platform detects hydrogen ions that are liberated as nucleotides are added stepwise to a 
replicating DNA template.  Every time a nucleotide is added to a growing chain being 
synthesized from a template DNA molecule being sequenced, a hydrogen ion is released 
as a byproduct of the reaction and this hydrogen ion is detected and recorded.  The Ion 
Torrent technology couples target DNA sequences (perhaps representing a collection of 
50-100 genes known to be associated with cardiac function) to micro beads that are 
situated in microwells of a metal-oxide semiconductor chip much like computer chips 
used in electronic devices.  Such “DNA chips” can have millions of these microwells, 
each harboring a particular fragment of DNA to be sequenced.  These wells are situated 
atop an ion-sensitive layer of the DNA chip that is able to detect the release of a 
hydrogen ion, which lowers the pH of the solution.  As individual dNTP solutions are 
washed over the chip loaded with the sequencing beads harboring DNA templates, a 
nucleotide in the dNTP solution may be incorporated into the complementary DNA chain 
as it is synthesized from the sequencing template.  When this occurs, a H+ ion will be 
released and detected.  Over the course of a sequencing run, 200-400 flows of dNTPs will 
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flood the chip sequentially and therefore the length of sequence produced may be 200-
400 nucleotides.12  
SNaPshotTM Method 
 The SNaPshotTM minisequencing kit from Thermo Fisher Scientific is an 
efficient tool for determining the nucleotide present at a particular position within a piece 
of DNA.13  Related to Sanger sequencing, SNaPshotTM utilizes the chain-terminating 
characteristic of ddNTPs that are fluorescently labeled.  However, rather than a mixture 
of dNTPs and ddNTPs, SNaPshotTM methods only use ddNTPs.  In the method, an 
oligonucleotide primer is synthesized that terminates one nucleotide 5’ to the site of a 
SNP site (perhaps the SNP responsible for a disease).  The DNA to be analyzed is heat 
denatured to single strands, hybridized to the oligonucleotide primer, and DNA 
polymerase extends the primer one nucleotide using the ddNTP and the nucleotide 
incorporated will be complementary to that existing at the SNP site.  Each ddNTP is 
covalently coupled to a different fluorescent dye: ddATP is green, ddGTP is blue, ddCTP 
is yellow (seen as black for enhanced visibility), and ddTTP is red.  The resulting short 
fluorescent DNA fragment is then separated by size using the 3130XL Genetic Analyzer 
(Applied Biosystems Inc., Foster City, CA) and the color of the fragment represents the 
ddNTP incorporated and therefore the nucleotide at that particular SNP site in the 
genomic DNA.  The SNaPshotTM method is robust and extremely efficient for SNP 
typing in genes for which SNP type polymorphisms are known.  SNaPshotTM technology 
is available in kit form from Applied Biosystems, Inc. and can be used to diagnose SNPs 
that are associated with genetic disorders.  In addition, by careful design of 
oligonucleotide primers, multiple SNPs, located within a single gene or among several 
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genes, can be interrogated simultaneously.13  An example of an electropherogram 
produced with SNP analysis is shown in Figure 1. 
 
Post-Mortem Molecular Autopsies 
The detection of gene mutations or pathogenic variations in genes associated with 
cardiac function and possibly leading to SCD often occurs after the death of an affected 
individual because so often death is the only clue for a possible gene defect existing in 
the victim.  A lack of overt external signs leading to a diagnosis makes it difficult for a 
medical examiner to conclude SCD as the cause of death.  Therefore, molecular genetic 
studies in the form of a “molecular autopsy” have gained popularity around the world to 
help confirm a cause of death.  A molecular autopsy exploits the molecular technology 
available today in order to search for an underlying genetic defect that would explain the 
death.  Without this information, the medical examiner is sometimes unable to 
Figure	  1.	  An	  example	  of	  an	  electropherogram	  with	  labeled	  peaks.	  	  Notice	  how	  TNNI3	  is	  homozygous	  (black	  box)	  for	  G	  and	  




conclusively identify the cause of death and also is unable to provide any useful 
information for the family of the victim who may also be at risk for inheriting the 
defective gene(s).10  This is especially true in the case of a victim of SCD where there is 
no physical or histological data available with which to identify the cause of death.  With 
a convincing diagnosis available to the ME resulting from the molecular autopsy, 
surviving family members can take appropriate lifestyle and medication changes to 
minimize their chance of suffering the same SCD fate.  Following the diagnosis 
genetically through the decedent’s family is referred to as family cascade testing to 
identify gene defects and their potential severity in the health of other potential victims in 
the family.7 
The search for biomarkers of SCD has occurred for some time.  A study by 
Carvajal-Zarrabal et al. used blood proteins as biomarkers that might be informative to 
identify the cause of death as SCD.14  This study used an immunoassay technique post-
mortem on 20 victims thought to have SCD.  Post-mortem blood samples were collected 
for the testing and a panel of proteins in the blood was investigated immunologically.  
One conclusion from the study was that “blood troponin levels may be useful to support a 
diagnosis of SCD”.14  Molecular autopsies can also help pathologists determine manner 
of death for many other causes when the toxicological analysis and gross autopsy both 
come back negative.15  
Selecting Genes 
 Literature exists describing possible associations of particular SNPs that might be 
associated with SCD.3,16  Genes that might be of diagnostic significance would have to 
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meet certain criteria: the proposed SNP effect would have to be non-synonymous (i.e. 
alter the amino acid sequence of the protein, or silence the gene as opposed to being one 
that does not change the amino acid sequence of the protein) and in using the 
SNaPshotTM assay, the gene defect would involve a nucleotide sequence substitution 
rather than a deletion or insertion in the DNA.  Tables and lists of SNPs in genes 
suspected to play a role in sudden cardiac death have been published and are summarized 
in a database made available to the public database hosted by NCBI 
(https://www.ncbi.nlm.nih.gov).16–18  Because of the large number of suspected SNP 
associations with genes known to be involved with cardiac function, it can be a 
challenging task to single out a handful for a population study using the SNaPshotTM 
methods.  Population studies are nonetheless needed to convincingly associate nucleotide 
sequence variations at SNP sites in relevant genes to SCD and thereby advance our 
ability to identify this condition as the cause of death in the medical examiner setting.19  
Selecting Primers 
To reliably genotype SNP sites in cardiac function genes using SNaPshotTM 
technology, one must design oligonucleotide primers that will hybridize to genomic DNA 
and terminate one nucleotide 5’ to the SNP site.  It is imperative to design a primer that 
will only find the specific SNP that a researcher is looking for.19  Attributes of a primer 
include length and nucleotide sequence, both of which will affect the annealing 
temperature in the PCR reactions as well as the specificity of the primer to target just one 
genomic site.  Software applications exist on the web that use the human genome 
database as a source of gene sequence to design primers that meet the required 
specifications.  Ideally, a collection of primers can be designed for the multiplex 
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SNaPshotTM reaction to interrogate simultaneously or multiplex SNP sites either within 
the same gene or in several.19  
National Database 
Annotated genes and their associated polymorphisms are catalogued for numerous 
species, including humans from several resources.  The National Center for 
Biotechnology Information, or NCBI (also called GenBank) is one such resource with 
DNA sequence information as well as some bioinformatics tools with which to study that 
sequence.19  The online database allows researchers to search freely and easily for 
biological information concerning genes and their variations.  Information from this 
database was used to identify candidate SNPs of potential importance to SCD and to 
identify specific nucleotide sequences to target with the primers used in the SNaPshotTM 
assay.   
U.S. National Library of Medicine (NLM)  
Another resource for information pertinent to the study reported here is the 
National Library of Medicine.  The United States National Library of Medicine, or NLM, 
maintains a sizeable database of print and electronic health information that is available 
to any individual.20  The library is the largest biomedical library in the world and is also 
one of the largest providers of digital content from the federal government.20  The free 
digital collection contains the identities and functions of numerous human genes and, 
where possible, gene defects responsible for health related phenotypes associated with 
those genes.  In addition to the brief description of a gene, references to published works 
are provided in the database for additional information.  The NLM database was of great 
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value in deciding which genes to include in a limited study of SNP polymorphisms in 
genes known to be involved in cardiac function.20  
Genes of interest to SCD  
EYA4  
 The gene EYA4 encodes a protein that is a putative oncogene linked to cancerous 
outcomes in previous research.20  EYA4 controls DNA repair and apoptosis, or controlled 
death of a cell, and these functions occur naturally in a living system.  Researchers have 
found that nucleotide sequence variations in this gene correlate with a cardiomyopathy 
causing ventricular dilation and impaired systolic function.  Dilated cardiomyopathy 
normally begins in the left ventricle and causes the chamber to stretch until it becomes 
too thin to effectively pump blood.17  Therefore, the gene EYA4’s mutations/variations 
are excellent candidates for our research with SCD.20 
 MYH6  
 MYH6 is an important cardiac gene directing the production of cardiac alpha (α)-
myosin heavy chain protein.20  The protein is one subunit of a larger protein in heart 
muscle cells called type II myosin.  These muscle proteins help convert energy into a 
mechanical force that is necessary for the heart to function and pump blood to the rest of 
the body.  Type II myosin helps to create the sarcomeres, the main cellular structures 
involved in the contraction of cardiac muscle.  Genetic mutations and pathogenic 
variations in this gene have been associated with dilated cardiomyopathy and premature 
deaths due to cardiac function failure. MYH6’s correlation to cardiomyopathy made it a 




TNNI3 is a gene that encodes the protein cardiac troponin I.20  Troponin I is a 
protein found only in the heart and is part of a troponin protein complex in the muscle 
cells connected with sarcomeres.  The troponin protein helps to regulate and coordinate 
the contractions of the heart.  Sequence variations in the TNNI3 gene have been found to 
cause a variety of cardiomyopathies: hypertrophic cardiomyopathy (thickening of the 
heart), restrictive cardiomyopathy (stiffening of cardiac muscle), and dilated 
cardiomyopathy.  These diseases can impair the heart function and hurt blood flow, 
which can lead to a premature cardiac death.20,21 
NEXN  
 The human gene NEXN encodes for a protein reportedly known to help with cell 
adhesion and migration.20  SNP-type variations in NEXN can cause pathologic conditions 
such as hypertrophic cardiomyopathy and dilated cardiomyopathy.  Both of these 
cardiomyopathies are hereditary.  Both of these disorders can also be worsened and 
provoked with intense exercise.  Hypertrophic cardiomyopathy can cause heart collapse, 
palpitations, and severe chest pain.20  
Summary 
Sudden cardiac death is an unexpected, tragic event that typically results in loss of 
life and shock for surviving family members.  SCD is likely a heterogenetic condition 
that may result from mutations or nucleotide sequence variations in a single gene, or from 
mutations/variations in a collection of genes that together compromise cardiac function 
and put the host at risk for cardiac failure under conditions of physical exertion.  To 
21	  
	  
better understand SCD, candidate SNPs that may affect cardiac function can be studied in 
a population of presumably normal individuals as well as among victims of unexplained 
death possibly linked to defects in cardiac function.  In this study, a small collection of 
SNP sites residing in several genes associated with cardiac function were studied using a 
single nucleotide sequencing technology known as SNaPshotTM.  While our study 
involved only a small sampling of genes and SNPs, we nonetheless anticipate adding to 








Single nucleotide polymorphisms, or SNPs, that may be correlated with sudden 
cardiac death (SCD) were identified using a method called SNaPshotTM.  Through the use 
of this method, it was possible to genotype 5 SNPs residing in 4 genes known to be 
associated with cardiac function and to attempt to correlate those genotypes with the 
cause of death in a cohort of DNA samples obtained from the Medical Examiner for the 
State of Oklahoma.  Many people fall victim to SCD in the United States each year and 
this research could help identify the mutations in cardiac function genes that underlie 
these untimely deaths.  
Choosing the Genes and SNPs 
  The genes and associated SNPs were chosen based upon the scientific literature 
available in this area that suggests these SNP/gene combinations are correlated with an 
elevated risk for SCD.3,5,10,16,18,20 The genome databases available to researchers contain 
the locations of SNPs within most human genes and also summarize studies that 
implicate those SNPs with disease.  In the cases of SNPs within genes associated with 
SCD, the pathogenicity of those SNPs is also suggested in some of the databases
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 available.  Those resources were used to choose the genes and SNPs for this study.  Once 
the candidate SNP was chosen, the National Center of Biotechnology Information 
(NCBI) website was used to obtain the nucleotide sequence of the DNA flanking the SNP 
and thus to identify primer binding sites used to amplify a DNA fragment harboring the 
SNP.  The individual webpages of the SNPs have sections that contain the nucleic acid 
sequences of the genes along with the highlighted SNPs contained within the genes.  
Right clicking the SNP and clicking “Reveal in Sequence View” shows a sequence that 
can be copied and pasted into software that will allow for the creation of primers for the 
SNaPshotTM assay to interrogate the SNP site.  This process was followed for each of the 
five SNPs chosen for this research: EYA4, EYA4-2, MYH6, TNNI3, and NEXN.  It is noted 
that the SNPs in EYA4 and EYA4-2 reside in different areas of the same gene and both 
have been reported to be “pathogenic”.19 
Creation of Primers 
 Primers are needed to specify areas on the DNA strand that harbors a SNP that 
may be associated with SCD.  The primers for the four genes and five SNPs were 
designed using the Primer 3: WWW Primer Tool available online from the Whitehead 
Institute for Biomedical Research 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi).  This primer design tool 
allows the user to design the 5’ and 3’ primers that will direct the amplification of a DNA 
fragment, design a hybridization probe for that amplicon, and determine the melting 
temperature range (Tm) of the primers.  The basepair size and Tm of the primers were the 
most important considerations in primer design for this study.  As will be discussed 
below, each SNP primer for the SNaPshotTM assay was designed with a different basepair 
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length in order to allow for differentiation of the various SNPs when using capillary 
electrophoresis.  Additionally, in order to maintain a consistent Tm for the primers to 
allow multiplexing of the SNaPshotTM reaction, adenosine residues were sometimes 
added to a primer in differing numbers.  Adding adenosines residues to a primer did not 
affect the Tm (because the A residues did not hybridize to the genomic DNA template) 
but did allow for engineering a primer of the desired size.  Thus, adenosine tails allow a 
PCR amplicon to become longer without affecting the Tm or the specificity of primer 
hybridization.  A total of three primers were made for each SNP or 15 primers altogether: 
a forward and reverse primer for first round of PCR in which a small genomic DNA 
segment harboring the SNP is amplified, and a third primer terminating one nucleotide 
upstream from the SNP site that is used to detect the nucleotide at that site using the 
SNaPshotTM reaction.  Table 2 lists the primers created for this study.  The table gives the 
gene name, amplicon size, direction of amplification, and the 5’-3’ sequence.  After the 






 DNA samples were obtained from two different population sources: OSU-CHS 
Human Identity Testing lab and the Tulsa Medical Examiner’s Office.  A total of 56 
extracted DNA samples that were deemed “normal” were obtained from the Human 
Table 2. Shown below are the primers being used in this research.  The gene name, length, direction, and sequence are all 
included. 
Gene Primer size (bp) Direction Sequence 5'-3' 
EYA4 20 Forward TCTCTCTCCCATCCCTCCTT 
EYA4 20 Reverse TGTAGAGCCAGAGGCATTGA 
EYA4 40 SNP AAAAAAAAAAAACTGTGTTCTTTAGCCGGAGATC 
EYA4-2 22 Forward TCAGAAACAAATGGGGCTGAGT 
EYA4-2 20 Reverse ACGCTCCATACGTTGATGCT 
EYA4-2 34 SNP AAAAAAAATTTCAGGATTATCCATCCTATACAGCCTTT 
MYH6 20 Forward GCTGGAGTGAACAGGGACAT 
MYH6 20 Reverse ACTGATAGGCGTTGTCGGAG 
MYH6 23 SNP AAAAAAAAAACATGCTGACCTTCCTGCAC 
TNNI3 21 Forward GGTCTTTATCCTGAAGCCCCG 
TNNI3 20 Reverse AGAAACCTCGCATCCTTGGG 
TNNI3 46 SNP AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGAGAGGCGGAGGAGCG 
NEXN 24 Forward AGCAGTCAACAATAAAGGATCTGC 
NEXN 21 Reverse CCGCCACAGAAAAGATGGATG 
NEXN 53 SNP ATCAGCTAAAAAAGAGAAGAAGAAAAGTGATTTTAAGGAAAAAAAAATTAATA 
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Identity Testing laboratory at OSU-CHS.  “Normal” in this study was defined as an 
individual surviving to age 40 or above.  Sudden unexplained deaths normally occur in 
individuals under the age of 35 or 40.22  The samples were labeled with a coding system 
that uses numbers and letters provided by the RT lab.  Since these samples were provided 
as anonymous no Institutional Review Board, or IRB, approval was needed for the study.  
The Tulsa Medical Examiner’s Office provided bloodstains from victims suspected of 
dying of cardiac related conditions.  The ME placed blood samples on blood collection 
cards prior to sending them to the lab; the cards were stored at room temperature at the 
OSU-CHS RT lab.  No IRB approval was needed for these samples since the cards were 
not labeled with names or other identifying information and the human subjects were 
deceased.   
DNA Extraction 
 An organic extraction method routinely used by the Human Identity Testing 
laboratory was used to extract and recover DNA from the ME samples.  The first step in 
DNA extraction was to prepare the bloodstain cuttings from the bloodstain cards supplied 
by the medical examiner.  A cutting of about 1/3 of the sample was placed into a 0.6 mL 
centrifuge tube that was labeled with the sample number and date.  After all the sample 
cuttings were made, fresh extraction buffer was prepared using 20 µL of 20-mg/ml 
proteinase K, 25 µL of 20% SDS, and 955 µL of TNE buffer (TNE is 10mM Tris-Cl, pH 
8.0 containing 0.2 M NaCl and 0.1 mM EDTA).  300 µL of this buffer was added to each 
tube of cuttings.  The tubes were mixed using a vortex mixer and placed in a 65°C heat 
block for 1 hour.  After 1 hour, the tubes were removed from heat and placed into a 1.5 
mL tubes that were labeled in the same way as the original tube.  A hole was punched in 
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the bottom of the small tube before placement into the larger tube and, upon 
centrifugation; the liquid extract containing the DNA was collected into the larger tube.  
The smaller tube containing the stain card remnants was discarded while the larger tube 
was kept for the next steps.  To each sample the following organic solvent mixture was 
added: 270 µL phenol and 30 µL chloroform/isoamyl mix (9:1).  Each tube was vortexed 
briefly and then centrifuged again at 10 000 rpm for 1 minute.  The emulsion created by 
vortex mixing is noticeably separated into an organic layer with phenol in the bottom 
phase and an aqueous phase containing the DNA in the top layer.  The top, aqueous phase 
could then be pipetted into a new tube, each labeled with the sample name.  There should 
be approximately 170 µL transferred.  Another 300 µL of the chloroform/isoamyl mix 
(above) was added to each tube that was then briefly mixed using a vortex mixer and then 
centrifuged at 10,000 rpm for 1 minute.  Again the top aqueous layer was transferred into 
a new 1.8mL tube.  DNA was then purified from the aqueous phase and concentrated by 
binding to a silica spin column (Zymo Research, Orange, CA).  This kit contains 
columns, wash buffer, and binding buffer to recover purified DNA from the initial 
extract.  The Zymo column was placed in a 1.8mL tube and the sample and binding 
buffer (about 400 µL) were added.  The tubes were then centrifuged at 10,000 rpm for 1 
minute.  Flow-through from the column in the bottom of the tube was discarded.  Next, 
200 µL of the wash buffer was added to the column and then it was centrifuged again for 
10 000 rpm for 1 minute.  The flow-through was not discarded after this step.  Another 
200 µL of wash buffer was added to the tube and centrifugation was repeated.  All flow-
through from this step and the step above was now discarded.  In a new tube, the sample 
was eluted by adding 15 µL of TE-4 (TE-4 is a 10mM Tris-Cl, pH 8.0 containing 0.1mM 
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EDTA) on top of the spin column, incubated 1 minute at room temperature, and then 
centrifuged at 10,000 rpm for 30 seconds.  The flow-through was retained and another 15 
µL TE-4 was added to the silica column and centrifuged again at 10,000 rpm for 30 
seconds.  The retained flow-through contains the eluted DNA in a total volume of about 
30 µL.  The samples were stored in a -20oC freezer.  
Preparing Primers 
 The primers received from Invitrogen are dry and must be reconstituted before 
use.  Primers were rehydrated in TE-4 to a concentration of 100 µM.  In order to dissolve 
the primers, TE-4 buffer was first added to each individual tube of the primers.  The 





In this formula C stands for concentration, V for volume, 1 for initial, and 2 for final or 
desired result.  There is also an easier way to determine this number.  When the primers 
arrive, each is accompanied with its own sheet titled “Invitrogen Custom Primers-
Certificate of Analysis.”  This sheet states the nano-moles (nmoles) of the primer; the 
amount varies for each primer depending upon each synthesis reaction.  That amount was 
then multiplied by 10, which is the amount of TE-4 buffer (in µL) that will be needed to 
produce primer stocks of 100 µM to the proper concentration.  Once all the primers were 
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resuspended to a concentration of 100 µM, 5 µL of the forward and reverse primers for 
each SNP was added to 40 µL of TE-4 in a 1.5 mL centrifuge tube to prepare a total of 50 
µL of 10X primer stock containing both the forward and reverse primers directing the 
amplification of the genomic DNA fragment harboring the SNP interrogated using 
SNaPshotTM.  It was also possible to prepare a 10X primer concentrate containing the 
forward and revers primers for all 5 SNPs such that the SNaPshotTM templates could be 
produced by multiplex PCR.  The final 10 µM stock was then used as the “working 
concentrate” for PCR or SNaPshotTM reactions.  The 100 µM stocks of each primer were 
stored at minus 20oC.     
Amplification of Genomic DNA Fragment Harboring a SNP 
 PCR amplifies a small region of the genomic DNA template to produce an 
amplicon with the SNP in the middle or near the middle of the amplicon.  Genomic DNA 
samples were taken from the freezer and thawed along with the forward/reverse primers.  
Genomic DNA samples were amplified with PCR in 12.5 µL reactions composed of 1.25 
µL primer mix, 7.5 µL GoTaq DNA polymerase (Promega Corp., Madison, WI), 3.25 µL 
nuclease free water, and 1 µL of genomic DNA.  A master mix minus the DNA was 
created and aliquoted into the number of PCR reactions tubes desired and then 1 µL DNA 
was added to each sample.  Once all the samples and a negative control have been 
prepared, they were amplified in an ABI9700 thermocycler (Applied Biosystems Inc., 
Carlsbad, CA).  The cycling program was: 98.0oC for 2 minutes for initial denaturation of 
the genomic DNA template followed by 30 cycles of 98oC for 10 seconds, 60oC for 1 
minute, 72oC for 30 seconds.  The program also had a single cycle of 60oC for 20 minutes 
for completion of the elongation and terminal adenosine addition. 
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 Following amplification of the DNA fragments to be used for the SNaPshotTM 
reaction, remaining PCR primers and dNTPs were destroyed by exposing amplification 
products to digestion with ExoSap (Affymetrix USB, Waltham, MA) which 
enzymatically degrades oligonucleotides and dephosphorylates dNTPs so that they 
cannot participate in further PCR amplification.   
Agarose gel electrophoresis  
The amount of amplified DNA produced in the first PCR reaction was roughly 
quantitated using agarose gel electrophoresis to ensure there was adequate DNA present 
in amplicons to obtain results from the SNaPshotTM reaction.  A 1% (v/v) agarose gel was 
prepared using Molecular Biology Grade Agarose LE powder (Phenix, Candler, NC), 1x 
TAE buffer, and GelRed dye (Phenix, Candler, NC) diluted 10,000x in the final liquid 
agarose gel mix when it was cool enough to touch and just before pouring the molten 
agarose into the gel mold. Five microliters of each amplified sample was mixed with 1 
µL of 5x loading dye (mix of bromphenol blue, xylene cyanol, and TAE buffer) in a 
centrifuge tube.  The prepared mix (6 µL total) was then pipetted into a sample well in 
the gel.  Once all the samples were loaded into the gel, the samples were electrophoresed 
at 100 Volts for a period of about 30 minutes or until the bromophenol blue tracking dye 
moved down the gel a distance of about 8-10 cm.  Once electrophoresis was complete the 
gel was removed from the electrophoresis apparatus and placed in the InGenious LHR 
Gel Imaging System by Syngene for analysis using a program called GeneSnap 
(SynGene, Bangalore, India).  The gel was illuminated on a UV light box and 
electrophoresis results were captured with a digital camera.  Sample results are shown in 




ExoSap-IT® PCR Product Clean Up 
The ExoSap procedure (Affymetrix USB, Waltham, MA) is used to “clean up” the 
samples and remove the leftover primers and dNTPs with a one-step enzymatic reaction.  
The reaction degrades residual PCR primers from the first amplification step and also 
destroys dNTPs that remain, preventing these reagents from participating in the 
SNaPshotTM reaction.  To remove unincorporated primers and dNTPs, 5 µL of PCR 
product was mixed with 2 µL of the ExoSAP-IT enzyme mixture.  Each sample tube was 
labeled with the name, date, and type of sample, such as: 13170M 11/10/17 EXO.  The 
tubes were briefly mixed and then briefly centrifuged.  Sample tubes were then incubated 
at 37°C for 1 hour followed by a 15 minute incubation at 80°C to inactivate the enzyme 
mixture.  Once this reaction was complete, the samples were ready for single nucleotide 
sequencing of the SNP site using the SNaPshotTM assay.   
 
 
Figure 2. An example of agaraose gel electrophoresis results.  The middle column labeled “L” is the size 
ladder. The other wells contain amplicons produced by PCR from genomic DNA samples. The two black 




 The ABI Prism® SNaPshotTM Multiplex Kit Protocol from Applied Biosystems, 
Inc. (Carlsbad, CA) was used to determine the nucleotide present at the SNP site located 
within each of the PCR amplicons produced in the step described above.  The 
SNaPshotTM reaction can interrogate up to 10 individual SNPs in a single capillary 
electrophoresis injection (manual provided with the SNaPshotTM kit from Applied 
Biosystems, Inc., Carlsbad, CA).  The SNaPshotTM kit (Thermo Fisher Scientific, 
Waltham, MA) contains a reaction mixture composed of buffer and dideoxynucleotide 
triphosphates like those used in Sanger DNA sequencing reactions.  Each ddNTP is 
labeled with a different colored fluorescent dye.  Being ddNTPs, they can become 
incorporated into a growing DNA chain, but the growth of the replicating DNA chain 
terminates once a ddNTP is incorporated.  Because the primer used to interrogate a SNP 
site terminates one nucleotide upstream from the site, a single ddNTP will become 
incorporated at the SNP site and the color of the resulting DNA fragment will specify the 
complementary nucleotide present at the SNP site in the DNA template.  Recall that 
SNaPshotTM primers were designed to be different lengths.  Therefore, following 
completion of the SNaPshotTM reaction, products are separated using capillary 
electrophoresis and the various lengths of the primers allows an investigator to trace each 
fluorescent peak in an electropherogram to a SNP interrogated with the procedure; the 
color of the peak will identify that nucleotide at the SNP site.  SNaPshotTM reactions were 
prepared by mixing 1 µL of each SNP primer (5 total) with 5 µL of nuclease free water to 
create 10 µL of a 10 µM mix of primers.  Next, 1 µL of the 10 µM primers were mixed 
with 49 µL of nuclease free water to create a 50 µL primer mix at a concentration of 0.2 
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µM.  Samples analyzed using SNaPshotTM included a positive control (supplied with the 
kit), and a negative control, as well as the products produced from the genomic DNA 
samples.  The 0.2 mL micro-centrifuge tubes were labeled according to name of sample, 
type of sample, and the date.  The mixtures used to prepare the samples are shown in 

















Sample 2.5 0.5 2 - 5 
Negative Control 2.5 0.5 - 2 5 
Positive Control 2.5 0.5 1 1 5 
 
Once SNaPshotTM reactions were created, samples were amplified using PCR.  The 
thermocycling program was as follows: 25 cycles of 96°C for 10 seconds, 50°C for 5 
seconds, 60°C for 30 seconds, followed by a cycle of 4°C for an infinite amount of time 
until the samples were removed.  Once amplification was complete, the samples were 
removed and treated with shrimp alkaline phosphatase (SAP) treatment to destroy any 
remaining unincorporated fluorescent ddNTPs that could interfere with data analysis.  
 




 The SAP treatment works much like the ExoSAP-IT; it helps to clean up the 
sample and prepare it for capillary electrophoresis.  This procedure used the samples 
from the SNaPshotTM reactions that were treated with SAP in a Shrimp Alkaline 
Phosphatase kit (USB®, Waltham, MA).  SAP reactions followed the Affymetrix USB 
procedure for dephosphorylation of ddNTPs: 5 µL of sample that resulted from the 
SNaPshotTM reaction mix was mixed with 1 µL SAP and 0.6 µL of SAP 10X Buffer.  The 
tubes were mixed and incubated for 60 minutes at 37° C and then 15 minutes at 65°C to 
inactivate further SAP activity. 
Capillary Electrophoresis and Data Analysis  
 Fluorescent SNaPshotTM products were separated by size using the 3130xl 
Genetic Analyzer (Applied Biosystems Inc., Foster City, CA), a capillary electrophoresis  
 
platform that separates DNA fragments by size and detects them using fluorescence.   








96-Well   












Table 4. Parameters for 3130xl Genetic Analyzer from ABI sequencing. 
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Data were collected using data collection software supplied with the instrument (Version 
3.0, ThermoFisher Scientific). Electrophoresis run parameters are listed in Table 4 above. 
Once the run was complete, GeneMapper analysis software (ver. 3.2, ABI Inc., Foster 
City, CA) was used to convert raw data into viewable results.    
Reading the Electropherogram Results 
 An example of SNaPshotTM results produced using the Gene Mapper software is 
shown in Figure 3.  The different colors define the ddNTP incorporated at each SNP site:  
Yellow (shown as black for visibility) represents an incorporated cytosine (C), blue 
represents incorporated guanine (G), red represents incorporated thymine (T), and green 
represents incorporated adenine (A).  Note that for genes in which the SNP exhibits a 
heterozygous genotype, the labeled SNaPshotTM products migrate with slightly different 
apparent molecular weights.  Because the size of the SNaPshotTM fragments is so small, 
the chemical characteristics of the different fluorescent dyes affects electrophoretic 
migration slightly during capillary electrophoresis and suggests the fragments may be 
different size.  For example, the SNP site in the EYA4-1 gene exhibits a red and a black 
Figure 3. Example of electropherogram results.   
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peak, which means that this SNP is heterozygous for T and C.  The chemical 
characteristics of the red and yellow (yellow is shown as black) fluorescent dyes affect 
electrophoretic migration and the heights of the fluorescent peaks reflect the fluorescence 
incorporated into the primer and thus the efficiency of the SNaPshotTM reaction for that 
particular SNP.  By knowing the nucleotide incorporated into the SNaPshotTM product 
one can deduce the nucleotide that is present at the SNP site in the template amplicon and 
assess its possible association with SCD. 
Statistical Analysis 
 Statistical analysis for the genotype data collected asked whether or not any 
differences observed in the frequency of SNP genotypes in normal or ME samples were 
significant.  A contingency table was produced to determine relationships between 
several variables.  The variables being compared were the “wildtype” (i.e. non-
pathogenic) verses “pathogenic” (i.e. perhaps associated with compromised gene 
function) genotype frequencies overall between the two population groups as well as 
between the individual SNP genotypes in individual genes.  The p-value or probability 
value of  <0.05 was chosen as the cut-off to test the significance, since that number is 
generally accepted as the boundary of scientific significance.23  The SNP sites were 
deemed significantly different or not in the contingency table if the lowercase letter after 
the frequency result for a given SNP matches that of another SNP, then the two sites are 
NOT significantly different.  If the two lowercase letters differ among SNP sites, then the 
proportion of wild type and pathogenic SNPs ARE significantly different in the normal 
versus ME population group.  A contingency table was created to compare the 
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differences in frequencies between the wildtype nucleotides and pathogenic SNPs in the 
normal and ME population groups.   
Population studies based upon the Hardy-Weinberg principle and linkage analysis 
were also applied to allele and genotype counts in the two population groups.  To begin 
the process, an allele frequency database was created.  The allele counts for the normal 
population were used to create an allele frequency databases for each SNP and these 
frequencies were used subsequently used to compare the expected versus observed 
genotype results in normal and ME samples to check for population equilibrium.  The 
Hardy-Weinberg equation p2+2pq+q2=1 will allow genotype frequencies for the 
different genotypes possible for a genetic marker to be accurately estimated if the 
population is in equilibrium.  The frequencies of the different allele forms of SNPs 
associated with EYA4, EYA4-2, TNNI3, and NEXN genes were sufficiently high to 
suggest these SNPs represent di-allelic genetic markers.  If these di-allelic markers are in 
equilibrium in the normal population, deviations from equilibrium in the ME population 
group would suggest an association of a SNP with SCD.  Moreover, if the different genes 
are unlinked in the normal population group, any sign of linkage in the ME group would 
be further support for an association of particular SNPs in our gene panel with SCD.  
Ultimately, chi square analysis was used to investigate any possible correlation of SNP 
genotypes with SCD.  Consideration was also given to an analysis of linkage among three 
genes in the panel as a cause of death, but this was not pursued since the number of ME 






RESULTS AND INTERPRETATION 
 
Sudden Cardiac Death (SCD) 
 Sudden cardiac death (SCD) occurs when the body experiences a sudden 
loss of blood due to the heart failing.1  While technological advances allow researchers to 
identify and examine variability in human DNA more efficiently than ever before, 
researching the hundreds of SNPs located within genes that have been linked to SCD in 
this study would have been prohibitively expensive.  Therefore, 4 genes harboring 5 
SNPs believed to be associated with compromised cardiac function were chosen for 
genotyping in a normal population and in a population of individuals thought to have died 
from cardiac episodes evaluated post-mortem by the Office of the Chief Medical 
Examiner for the State of Oklahoma.  The genes studied included: EYA4, MYH6, 
TNNI3, and NEXN.  
Five different SNPs were researched in this study in the four genes previously 
mentioned.  The genes were chosen for this study in two ways: In a unpublished study 
performed by Dr. Di Shen (a visiting research scientist from Beijing, China), several 
DNA samples obtained from the Office of the Chief Medical Examiner were subjected to
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massively parallel DNA sequencing (MPS) of a library of 58 genes known to be involved 
in cardiac function, some of which have been implicated in SCD.  Results from the 
sequencing identified numerous SNPs contained within the 58 genes sequenced, some of 
which were chosen for this study (NEXN, EYA4, and TNNI3).  Also considered in 
gene/SNP selection was the literature that exists concerning SCD and the confidence 
values reported for associations of particular SNPs with pathology that may be causative 
of SCD.  The SNPs associated with the NEXN, EYA4, TNNI3, and MYH6 genes among 
those suggested in the literature good candidates for this.  
 The samples subjected to SNaPshotTM genotyping were acquired from the Office 
of the Chief Medical Examiner for the State of Oklahoma and from the Oklahoma State 
University Center for Health Sciences’ Human Identity Testing laboratory.  The twenty-
eight medical examiner (ME) samples were provided as bloodstains from individuals 
who may have died due to SCD or other cardiac conditions.  One sample provided by the 
ME’s office was thought to have died from SCD with high confidence(Sample 1 in Table 
7), since it was obtained from an infant who died suddenly for no apparent cause.  This 
sample exhibited a genotype that contained pathogenic SNPs at each of the 5 SNP sites in 
the four genes that were used in our study (Table 5). 
The 56 DNA samples from the OSU Human Identity Testing laboratory had 
already been extracted and thus, with rare exception, DNA extraction was not required.  
The OSU samples were from individuals past the age of 40.  It was presumed that if the 
people did not have a cardiac episode before age 40, then they could legitimately be 
deemed at low to no risk for SCD since this diseases generally strikes relatively early in 
life.  These samples were thus considered to represent the normal population group.   
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Genomic DNA samples obtained from normal donors and those obtained from the 
Medical Examiner were amplified using PCR to produce the template for the SNaPshotTM 
assay.  However, prior to performing the SNaPshotTM assay, the amplicons produced 
were assessed for quality by agarose gel electrophoresis.  Products suitable for further 
analysis were visualized in a stained gel as a single band of about 150 bp (basepairs) that 




Figure	  4.	  Amplicon	  produced	  by	  PCR	  	  using	  5	  sets	  of	  primers	  to	  amplify	  templates	  for	  SNaPshotTM	  
reactions.	  	  Products	  were	  separated	  by	  electrophoresis	  in	  0.7%	  agarose	  gel	  electrophoresis,	  with	  
GelRed	  and	  1xTAE	  buffer.	  	  These	  PCR	  amplicon	  products	  served	  as	  template	  for	  the	  SNaPshotTM	  assay.	  	  
Molecular	  weight	  standard	  models	  are	  shown	  in	  between	  the	  4/5	  lanes	  and	  the	  lane	  labeled	  “L”.	  The	  
first	  black	  band	  is	  desirable	  DNA	  product	  (example	  shown	  by	  blue	  arrow)	  and	  the	  second	  (green	  
arrow)	  is	  unincorporated	  nucleotides	  and/or	  primers.	  
41	  
	  
SNaPshotTM Results  
 The single nucleotide polymorphisms (SNP) were characterized using 
SNaPshotTM methodology.  SNP sites were researched using the National Center for 
Biotechnology Information (NCBI) database.  This database provides the gene identity 
and description, the chromosomal location, any aliases, and other useful information 
about any particular gene and polymorphisms or mutations within that gene.  The wild 
type and nucleotide variants for the five SNPs chosen for this study are listed in Table 5. 
below.  NCBI lists all five of the variant genotypes as potentially pathogenic.  A SNP, 
although changing the DNA sequence, is not always harmful to the host.  However, if a 
SNP is defined as pathogenic, then it is linked to a disease and has the potential to cause 
or contribute to said disease.  A SNP may alter the amino acid sequence of a gene product 
and result in the loss of function for that protein.  Such a SNP would therefore be 
designated pathogenic and could contribute to SCD.  
Table 5. The wildtypes and variants for the five loci tested in this research. 
Locus  Pos GRCh37 dbSNP ID Wildtype Variant 
EYA4 133849966 rs3734279 C T 
EYA4-2 133789728 rs9493627 G A 
MYH6 23874889 rs140596256 G A 
TNNI3 55667647 rs3729711 G T 
NEXN 78408536 rs3767028 G C 
 
 SNaPshotTM results are visualized using capillary electrophoresis (CE).  
Following the SNaPshotTM reaction, the oligonucleotides that have been extended by 
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one base are separated from one another electrophoretically using CE with the 3130XL 
Genetic Analyzer.  A successful SNaPshotTM reaction was scored if there was adequate 
fluorescence associated with an amplicon (i.e. the fluorescence met or exceeded a 
threshold value) and if the fluorescent peak was of expected size.  Heterozygosity was 
determined if peaks of two colors were detected at a particular SNP site and if the peak 
heights were balanced, had a characteristic triangular peak shape, and if fluorescence 
exceeded 50 rfu.  Examples of true and false SNP genotypes are shown in Figures 5a and 
5b respectively.  The arrow in Figure 5a identifies the “A” peak for the SNP associated 
with the gene MYH6.  We would conclude that this is not a true A-allele (i.e. the 
incorporation of adenosine at this SNP site is an artifact) since the peak does not have a 
true, characteristic peak shape and also the peak height is severely imbalanced with the 
G-allele to the left of the artifact.  In Figure 5a, all SNPs among the 5 genes analyzed 
exhibit homozygosisty.  Figure 5b shows results in which the EYA4-2 gene exhibits 
heterozygosity with an A residue incorporated to complement a T residue on one 
chromosome whereas the other chromosome harbors a C residue (because of the 
incorporation of a G residue in the SNaPshotTM assay).  Peak heights are balanced 





SNaPshotTM Genotyping Results 
 SNaPshotTM genotypes for the five genes among the normal and ME samples are 
summarized in Tables 6 and 7.  Some samples yielded results that were questionable for 
Figure5a.	  An	  electropherogram	  of	  a	  normal	  sample	  shown	  from	  program	  GeneMapper	  using	  ABI	  3130	  for	  sequencing.	  	  SNP	  
sites	  MYH6,	  EYA4,	  EYA4-­‐2,	  TNNIE3,	  and	  NEXN	  are	  all	  on	  the	  panel.	  	  MYH6	  does	  not	  have	  a	  true	  peak	  for	  nucleotide	  A	  due	  to	  
its	  unusual	  shape,	  as	  shown	  by	  the	  red	  arrow.	  	  
Figure	  5b.	  An	  example	  of	  a	  successful	  electropherogram.	  	  The	  adenosine	  peak	  for	  MYH6	  is	  not	  called	  due	  to	  its	  imbalance	  and	  




various reasons and DNA had to be re-extracted and the SNaPshotTM reaction repeated.  
In total, there were 94 repetitions of SNaPshotTM assays and the results shown in Tables 6 
and 7 were all-reproducible and represent the consensus genotypes.  The presence of a 
“wildtype” nucleotide at a SNP position is denoted in black typeface whereas the 
presence of a “variant” nucleotide at that position is denoted in red typeface.  Variants 
may represent true mutations that are pathologic with respect to the functioning of the 
gene in question.  However, variants by themselves may not seriously affect gene 




Sample	  Name	   MYH6	   EYA4	   EYA4-­‐2	   TNNI3	   NEXN	  
	  	   G	  to	  A	   C	  to	  T	   G	  to	  A	   G	  to	  T	   G	  to	  C	  
SAM	   GG	   CC	   GG	   GG	   GG	  
13170M	  	   GG	   CC	   AA	   GG	   GG	  
13493AV	  	   GG	   CC	   GG	   GG	   CC	  
13531AF	  	   GG	   CT	   GG	   GG	   GG	  
13532M	   GG	   TT	   AA	   GG	   GG	  
13534AF	  	   GG	   CT	   GA	   GG	   GG	  
13550M	  	   GG	   CC	   AA	   GG	   GG	  
13607AF	  	   GG	   CC	   GG	   GG	   GG	  
13624M	  	   GG	   CT	   GG	   GG	   GC	  
13649M	  	   GG	   TT	   GA	   GG	   GG	  
13654AF	  	   GG	   CT	   GG	   GG	   GG	  
13682M	  	   GG	   CT	   GA	   GG	   GC	  
13695M	  	   GG	   CC	   GA	   GG	   GG	  
13697M	   GG	   CC	   GG	   GG	   GG	  
13701AF	  	   GG	   CT	   GA	   GG	   GG	  
13729M	  	   GG	   CT	   GG	   GG	   GG	  
13505M	  	   GG	   CT	   GG	   GG	   GG	  
13492AF	   GG	   CT	   GA	   GG	   GG	  
13493M	   GG	   CC	   GG	   GG	   GC	  
13505M	  	   GG	   CT	   GG	   GG	   GG	  
13533M	   GG	   CC	   GA	   GG	   GG	  
13534AF	  	   GG	   CT	   GA	   GG	   GG	  
13540AF	   GG	   CC	   GG	   GG	   GG	  
13546AF	   GG	   CC	   GG	   GG	   GG	  
13547M	   GG	   CT	   GA	   GG	   GG	  
13550AF	   GG	   CC	   GA	   GG	   GG	  
13551AF	   GG	   CT	   GA	   GG	   GG	  
13559AF	   GG	   TT	   AA	   GG	   GG	  
13563AF	   GG	   TT	   AA	   GG	   GG	  
13602M	   GG	   CC	   GA	   GG	   GG	  
13622S3	   GG	   CT	   GA	   GG	   GG	  
13624M	  	   GG	   CT	   GG	   GG	   GC	  
13624M	  	   GG	   CT	   GA	   GG	   GC	  
13636APA	   GG	   CT	   GA	   GG	   GC	  
Table	  6.	  The	  SNP	  results	  for	  “Normal	  Samples”.	  The	  red	  colored	  nucleotides	  represent	  variant	  
nucleotides	  while	  those	  in	  black	  represent	  the	  wild	  type.	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13636M	   GG	   TT	   GG	   GG	   GC	  
13647AF	   GG	   CT	   AA	   GT	   GG	  
13648AF	   GG	   CC	   GG	   GG	   CC	  
13648M	   GG	   CT	   GA	   GG	   GC	  
13649M	   GG	   TT	   GA	   GG	   GG	  
13654AF	   GG	   TT	   GA	   GG	   GG	  
13664AF	  	   GG	   CT	   AA	   GG	   GG	  
13668AF	  	   GG	   CC	   GG	   GG	   CC	  
13673AF	   GG	   CC	   GG	   GG	   GG	  
13677M	   GG	   TT	   GA	   GG	   GG	  
13682AF	   GG	   CT	   GG	   GG	   GG	  
13689AF	   GG	   TT	   GA	   GG	   GG	  
13696AF	  	   GG	   CT	   GA	   GG	   GC	  
13712AF	   GG	   CC	   GA	   GT	   GC	  
13720S2	   GG	   TT	   AA	   GG	   GG	  
13726AF	   GG	   CC	   GG	   GG	   GC	  
13729M	  	   GG	   CT	   GG	   GG	   GG	  
13731AP	   GG	   CT	   GA	   GG	   GC	  
13731M	   GG	   CC	   GA	   GG	   GG	  
13745APA	   GG	   CC	   GG	   GG	   GC	  
13745M	   GG	   CT	   GA	   GG	   GC	  




Sample	  Name	   MYH6	   EYA4	   EYA4-­‐2	   TNNI3	   NEXN	  
	   G	  to	  A	   C	  to	  T	   G	  to	  A	   G	  to	  T	   G	  to	  C	  
1	   GA	   TT	   GA	   GT	   GC	  
5	   GG	   CT	   GA	   GT	   GG	  
6	   GG	   CC	   GG	   GG	   GG	  
7	   GG	   TT	   GA	   GG	   GC	  
9	   GG	   CC	   AA	   GG	   GG	  
10	   GG	   CT	   GG	   GG	   GC	  
11	   GG	   CT	   GA	   GG	   GG	  
12	   GG	   CC	   GG	   GG	   GG	  
13	   GG	   TT	   GG	   GG	   GG	  
14	   GG	   TT	   GG	   GG	   GG	  
19	   GG	   CC	   GA	   GG	   GG	  
21	   GG	   CT	   GA	   GT	   GG	  
24	   GG	   CC	   AA	   GG	   GG	  
26	   GG	   TT	   GG	   GG	   GG	  
27	   GG	   CT	   AA	   GG	   GG	  
28	   GG	   CT	   GA	   GG	   GG	  
29	   GG	   CT	   GG	   GG	   GG	  
30	   GG	   CT	   AA	   GG	   GG	  
32	   GG	   CT	   AA	   GG	   GG	  
33	   GG	   CT	   AA	   GG	   GG	  
34	   GG	   CT	   AA	   GG	   GG	  
35	   GG	   CT	   GG	   GG	   GG	  
36	   GG	   TT	   AA	   GG	   GG	  
37	   GG	   CT	   GG	   GG	   GG	  
38	   GG	   CT	   GA	   NONE	   CC	  
39	   GG	   CT	   GG	   GG	   GG	  
40	   GG	   CT	   GG	   GG	   GG	  
41	   GG	   TT	   GA	   GG	   GC	  
 
After all SNP genotypes were determined, a count was made to define and compare the 
number of pathologic versus non-pathologic SNPs among the 5-gene panel in the two 
population groups.  The numbers can be seen in Table 8 below.  From this data, the 
Table	  7.	  The	  SNP	  results	  for	  the	  medical	  examiner	  sample	  results.	  The	  variant	  nucleotides	  
are	  marked	  in	  red	  while	  the	  wild	  type	  nucleotides	  are	  shown	  in	  black.	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percentages of pathogenic and wildtype nucleotides found in each population group is 
shown in Table 9.   
 
 
Normal	   MYH6	   EYA4	   EYA4-­‐2	   TNNI3	   NEXN	  
Mutation	   0%	   40.18%	   37.50%	   1.79%	   17.86%	  
Wildtype	   100%	   59.82%	   62.50%	   98.21%	   82.14%	  
	   	  
ME	   MYH6	   EYA4	   EYA4-­‐2	   TNNI3	   NEXN	  
Mutation	   1.79%	   53.57%	   44.64%	   5.56%	   10.71%	  
Wildtype	   98.21%	   46.43%	   55.36%	   96.30%	   89.29%	  
	   	   	   	   	   	  
	  
Total	  Percentages:	  
Normal	  Mutation:	  19.46%	   Normal	  Wildtype:	  80.54%	  
ME	  Mutation:	  23.38%	   ME	  Wildtype:	  76.62%	  
 
The data from Table 8 from the normal population group can also be used as the 
population frequencies for the alternate forms of the SNP alleles for the di-allelic genetic 
markers. The designation of a nucleotide sequence variant as an allele for a genetic 
marker (as opposed to a mutation) is generally dependent upon the frequency of the 
variant in the population, which must exceed a frequency of 1%.  The single “A” residue 
Table	  9.	  The	  percentages	  of	  mutation/variations	  and	  wildtype	  mutations	  found	  in	  each	  SNP	  
site	  according	  to	  sample	  group.	  
Table	  8.	  The	  counts	  for	  varied	  and	  wildtype	  nucleotides	  found	  in	  “normal”	  and	  ME	  sample	  groups.	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detected in an ME sample for the MYH6 SNP may therefore represent a true mutation 
inasmuch this one pathogenic allele was observed in both population groups, even though 
its frequency exceeds 1% (i.e. 1.78%).  For the remaining SNPs in the different genes, the 
possible variants look more like the alleles of a di-allele genetic marker (Table 8).  
Regardless of whether a SNP is an allele for a di-allelic system or a mutation, according 
to the NCBI, variant SNPs for the genes analyzed here are considered potentially 
“pathologic” for gene function and therefore an individual harboring a variant may be 
considered at elevated risk for cardiac events. 
Considering all SNPs as a group among the normal and ME populations, the 
percentage of wild type alleles is higher than the percentage of pathogenic alleles in both 
population groups as seen in Table 9.  Considering each gene individually, the numbers 
of wildtype SNPs was higher than the variants except for the EYA4 gene in the ME 




Normal	  Sample	  Gene	  Frequencies	  
SNPs	  
MYH6	  	  
(G-­‐A)	   EYA4	  (C-­‐T)	  
EYA4-­‐2	  	  
(G-­‐A)	   TNNI3	  (G-­‐T)	   NEXN	  (G-­‐C)	  
Non	  Path	   G	   1	   C	   0.598	   G	   0.625	   G	   0.982	   G	   0.821	  
Path	   A	   0	   T	   0.402	   A	   0.375	   T	   0.018	   C	   0.179	  
	   	   	   	   	   	   	   	   	   	   	  ME	  Sample	  Gene	  Frequencies	  
SNPs	   MYH6	  (G-­‐A)	   EYA4	  (C-­‐T)	   EYA4-­‐2	  (G-­‐A)	   TNNI3	  (G-­‐T)	   NEXN	  (G-­‐C)	  
Non	  Path	   G	   0.982	   C	   0.464	   G	   0.554	   G	   0.944	   G	   0.893	  
Path	   A	   0.018	   T	   0.536	   A	   0.446	   T	   0.056	   C	   0.107	  
 
Statistical Analysis of SNaPshotTM Genotypes 
 A contingency table was created for the allele counts to see if the frequency of 
wildtype and variant SNPs differed between the normal population group and the group 
represented in medical examiner samples (Table 10). Contingency tables examine 
relationships between multiple variables.  The variables analyzed in this table are the 
frequency of wild type versus variant SNPs in the medical examiner samples and in the 
normal sample group. The SNP sites in the different genes were also compared with one 
another.  The chi square results at the bottom of the tables are both <0.0001 for the ME 
and normal sample groups (Table 11).  Since the p-value is less than 0.05, the difference 
in the frequency of wildtype and variant SNPs are significantly different between the 
normal and ME sample group.  Thus, the higher frequency of pathogenic alleles in the 
Table	  10.	  The	  gene	  frequencies	  for	  the	  alleles	  in	  normal	  samples	  and	  medical	  examiner	  samples.	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ME group is statistically different from their frequency in the normal group suggesting a 
relationship between the pathogenic SNPs detected and cardiac function defects 
contributing to death.  Comparisons that are NOT significantly different from each other 
within each group are labeled with the same lowercase letter following the p-value 
whereas SNP sites that ARE significantly different have a different lowercase letter 
following the p-value (Table 11).  Thus, in the ME sample group, pathogenic allele 
frequencies for SNPs at the EYA4 and EYA-4 loci are not significantly different from 
each other, both being denoted by the letter “a”.  NEXN, TNNI3, and MYH6 are also not 
significantly different from each other in terms of the frequency of pathogenic alleles.  In 
the normal sample group, the frequencies of wild type and pathogenic alleles at the 
EYA4 and EYA4-2 loci again are not significantly different from each other.  
Interestingly however, although the frequency of pathogenic and wild type SNPs residing 
at the TNNI3 and MYH6 loci are not significantly different from each other, the 
frequency of pathogenic and wild type SNPs at the NEXN locus is significantly different 





Other Population Analyses 
 The Hardy-Weinberg principle can be used to predict genotype frequencies for a 
genetic marker in equilibrium in the population using allele frequencies for the 
predictions.24  The predicted genotype frequencies for the 5 SNP markers were computed 
using allele frequencies obtained from the normal population group (Table 10).  The 
predicted genotype frequencies were then compared with the observed genotypes for both 
the normal and ME population groups to determine if the 5 SNP markers are in 
equilibrium.  Results of the H-W analysis of the SNP markers showed that both the 
normal population and ME populations appear to be in equilibrium for all 5 SNP markers 
ME	  Sample	  Group	  
	  	   EYA4	   EYA4-­‐2	   MYH6	   NEXN	   TNNI3	   Total	  
Nonpathogenic	   26	   31	   55	   50	   51	   213	  
Pathogenic	   30	   25	   1	   6	   3	   65	  
Frequency	   53.57a	   44.64a	   1.79b	   10.71b	   5.56b	   	  
Total	   56	   56	   56	   56	   54	   	  
	  	   	   	   	   	   	   	  
	   	   	   	   	   	   	  
Normal	  Sample	  Group	  
	  	   EYA4	   EYA4-­‐2	   MYH6	   NEXN	   TNNI3	   Total	  
Nonpathogenic	   67	   70	   112	   92	   110	   451	  
Pathogenic	   45	   42	   0	   20	   2	   109	  
Frequency	   40.18a	   37.50a	   0.00c	   17.86b	   1.79c	   	  
Total	   112	   112	   112	   112	   112	   	  
	  	   	  	   	  	   	  	   	  	   Chi	  Square	   <0.0001	  
Table	  11.	  The	  contingency	  table	  comparing	  the	  relative	  frequencies	  of	  wildtype	  and	  pathologic	  alleles	  
in	  the	  normal	  population	  and	  in	  the	  ME	  group	  of	  samples.	  	  The	  colors	  help	  to	  denote	  which	  SNP	  sites	  




(Table 12).  The EYA4-2 SNP comes close to being in disequilibrium in the ME group, 
however the p-value is still greater that 0.05 and therefore we must conclude that the 
evidence does not support this marker being in disequilibrium within the population. 
 
 
Chi	  Square	  Results	  for	  Expected	  vs	  Observed	  
SNP	   Normal	  Population	  
ME	  
Population	  
MYH6	  (G-­‐A)	   N/A	   N/A	  
EYA4	  (C-­‐T)	   0.867	   0.113	  
EYA4-­‐2	  (G-­‐A)	   0.998	   0.064	  
TNNI3	  (G-­‐T)	   0.991	   0.099	  
NEXN	  (G-­‐C)	   0.542	   0.216	  
 
In an extension of the H-W analysis, it was also possible to determine if the 
frequencies of paired genotypes for two SNP markers were significantly different in the 
normal and ME population groups.  Since SCD almost certainly can involve gene defects 
in multiple genes, a statistical analysis of paired SNPs might support a multi-gene cause 
of the underlying cardiac defects leading to death in the ME sample group.  The observed 
results versus the expected results were examined, and the p-value was determined for all 
SNP site di-allelic comparisons.   
Table	  12.	  The	  expected	  versus	  observed	  chi	  square	  results	  for	  the	  normal	  and	  
ME	  sample	  population.	  Since	  the	  p-­‐values	  are	  all	  greater	  than	  0.05,	  the	  
difference	  between	  the	  expected	  and	  observed	  is	  not	  significant.	  However,	  the	  









Results from the statistical analysis of expected versus observed genotypes from pairwise 
combinations of SNP markers are shown in Table 14a and 14b for EYA4 (blue) versus 
MYH6 (red).   
 MYH6 EYA4 EYA4-2 TNNI3 NEXN 
p G 1 C 0.598 G 0.625 G 0.982 G 0.821 
q A 0 T 0.402 A 0.375 T 0.018 C 0.179 
Table	  13.	  The	  Hardy-­‐Weinberg	  phenotype	  predictions	  using	  allele	  






Expected	  Combination	  in	  EYA4xMYH6	  
CCxGG	   0.358	   CTxGA	   0	   CTxAA	  
TTxAA	   0	   CCxGA	   0	   0	  
CCxAA	   0	   TTxGA	   0	   Total:	  
TTxGG	   0.161	   CTxGG	   0.481	   1	  
Expected	  Combination	  in	  Population	  in	  EYA4xMYH6	  
CCxGG	   20.040	   CTxGA	   0	   CTxAA	  
TTxAA	   0	   CCxGA	   0	   0	  
CCxAA	   0	   TTxGA	   0	   Total:	  
TTxGG	   9.040	   CTxGG	   26.920	   56	  
Observed	  Combination	  in	  Population	  in	  EYA4xMYH6	  
CCxGG	   21	   CTxGA	   0	   CTtxAA	  
TTxAA	   0	   CCxGA	   0	   0	  
CCxAA	   0	   TTxGA	   0	   Total:	  
TTxGG	   10	   CTxGG	   25	   56	  
 
  
Table	  14a.	  The	  results	  for	  phenotype	  combinations	  between	  EYA4	  and	  
MYH6	  for	  the	  normal	  sample	  group.	  	  EYA4	  phenotypes	  are	  shown	  in	  blue	  
while	  the	  MYH6	  phenotypes	  are	  in	  red.	  The	  allele	  frequencies	  were	  





	  EYA4xMYH6	   Expected	   Observed	   Difference	   Chi	  Square	  
CCxGG	   20.040	   21	   0.960	   0.867	  
TTxGG	   9.040	   10	   0.960	   >0.05	  
CTxGG	   26.920	   25	   1.920	  
Not	  
Significant	  CTxAA	   0	   0	   0	  
TTxAA	   0	   0	   0	  
	  CCxAA	   0	   0	   0	  
	  CTxGA	   0	   0	   0	  
	  CCxGA	   0	   0	   0	  
	  TTxGA	   0	   0	   0	  
	   
If the combinations of genotypes harboring pathogenic SNPs are suggested to correlate 
with cardiac defects, the p-value calculated with chi-square analysis would be <0.05.  The 
chi-square result produced from a comparison of expected versus observed SNP 
phenotypes for EYA4 combined with MYH6 in the normal population group is 0.867.  
Therefore, this combination of genotypes appears to be unlinked and phenotypes 
randomly associate depending, as predicted by multiplying the individual genotype 
frequencies.  Table 15 shows the similar analysis for all the pairwise genotype 
combinations in the normal and ME population groups.  In the normal population group, 
each pair of SNP markers is observed to occur with the expected genotype frequency.  
Therefore, the 5 SNPs appear to all be unlinked in the normal population group.   
Table	  14b.	  The	  chi	  square	  results	  for	  the	  pairwise	  combinations	  of	  phenotypes	  for	  
EYA4	  and	  MYH6	  in	  the	  normal	  samples.	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The ME samples, however, did show a significant difference in the expected 
versus observed frequencies of pairwise genotype combinations (Table 15).  For every 
pairwise combination except MYH6 X TNNI3, p-values were less than 0.05, and some 
combinations were extremely significant (EYA4-2 X TNNI3 for example with p=1.13 X 
10-7). These results suggest that, among the group of DNA samples from victims of 
cardiac related deaths, there is a significant association of pairs of genotypes containing 
pathogenic alleles.  Such genotype combinations may act synergistically to elevate the 
risk for cardiac defects leading to death.  These results also support the notion that SCD 
is a heterogenetic condition.  
The smaller a p-value (shown in “P-Value” column in Table 15) is, the stronger 
the suggested association.  Therefore, p values produced from the pairwise comparisons 
shown in Table 15 might predict the “strength” of a given combination of pathogenic 
alleles in elevating the risk for cardiac related death.  Under this hypothesis, the EYA4-
2/TNNI3 SNP combination, which has a p value of 1.13 X 10-7, would represent a 
combination of pathogenic alleles that carries the highest risk for cardiac defects leading 
to death.  Table 15 lists the gene SNP combinations in order of most correlated (lowest p-
value) to least correlated (highest p-value) for the ME comparisons.   
Performing the same exercise comparing expected and observe genotypes for 
three SNP markers was not undertaken because of the small size of the populations from 







Combination	   Sample	  Type	   P-­‐Value	  
EYA4-­‐2/TNNI3	   Normal	  	   0.9488	  
	   ME	   1.1344E-­‐07	  
EYA4-­‐2/NEXN	   Normal	  	   0.1260	  
	   ME	   2.6728E-­‐05	  
EYA4/EYA4-­‐2	   Normal	  	   0.1472	  
	   ME	   0.0003	  
EYA4/TNNI3	   Normal	  	   0.9991	  
	   ME	   0.0014	  
MYH6/EYA4-­‐2	   Normal	  	   0.9057	  
	   ME	   0.0020	  
EYA4/NEXN	   Normal	  	   0.1017	  
	   ME	   0.0025	  
TNNI3/NEXN	   Normal	  	   0.9811	  
	   ME	   0.0237	  
MYH6/EYA4	   Normal	  	   0.8673	  
	   ME	   0.0308	  
MYH6/NEXN	   Normal	  	   0.5423	  
	   ME	   0.0346	  
MYH6/TNNI3	   Normal	  	   0.9908	  
	   ME	   0.2655	  
Table	  15.	  The	  chi	  square	  results	  for	  the	  di-­‐allelic	  combinations	  in	  the	  normal	  sample	  
groups	  and	  the	  ME	  sample	  groups.	  	  The	  combinations	  did	  not	  correlate	  with	  SCD	  if	  
the	  p-­‐value	  result	  was	  higher	  than	  0.05,	  and	  the	  combinations	  were	  correlated	  to	  






DISCUSSION AND CONCLUSIONS 
 Sudden cardiac death (SCD) is the name given to an unexpected death with no 
obvious outward cause that occurs in one who has no history of cardiac problems.  SCD 
can result from conditions affecting the heart muscle such as cardiomyopathy, and often 
SCD results from a defect in the electrical system controlling heart muscles contraction 
creating irregularities in the heartbeats.  The sudden stop in cardiac function causes the 
victim to lose consciousness, which makes it difficult for first responders to understand a 
victim’s situation and provide emergency care.  The main concern for a victim of SCD is 
the loss of blood flow to the brain, which can cause severe brain damage.   
 SCD is rooted in defects in one or more members of a collection of genes that are 
all associated with cardiac function.  Nucleotide sequence variations in one of these genes 
may only marginally affect gene function or a sequence variation may silence gene 
expression altogether.  Nucleotide sequence variations in individual genes that are not 
lethal by themselves may contribute to an overall increase in the risk of SCD when a 
collection of genes with variant nucleotide sequences is considered as a group.  The 
spectrum of effects resulting from nucleotide sequence variations in the large number of 
genes associated with cardiac function is likely responsible for heterogeneity in SCD in 
terms of the age of a victim and also for the difficulty in detecting particular anomalies in
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cardiac function that would be revealed in typical physical exams.  The one consistent 
feature of SCD is the premature death of young people.1 
Although limited physical or histological evidence of SCD is available from 
victims to use diagnostically, a lot is known about genes involved with cardiac function 
and the study of such genes may facilitate identifying gene variants that are correlated 
with defects in cardiac function.  Cardiomyopathies are a common type of heart defect 
and, of the four principal types, hypertrophic cardiomyopathy (HCM) has been 
implicated in a high proportion of athletic deaths.11  All four types of cardiomyopathy 
have been associated with variations in the nucleotide sequence of members of a panel of 
genes associated with cardiac function.11   
Most SCD diagnoses are made post-mortem since many of the clues associated 
with SCD are missed during routine or even detailed physical exams.  As stated 
previously, the lack of physical symptoms also makes it difficult for medical examiners 
or pathologists to determine cause of death and in some cases SCD is listed as the cause 
of death when no other cause can be identified.  Molecular autopsies have gained 
popularity for this reason.  Post-mortem genetic studies can help to confirm cause of 
death by analyzing the victim’s DNA, searching for nucleotide sequence variations that 
could have affected cardiac function in a lethal way.  Besides being able to provide a 
cause of death, diagnosis of SCD is important in order to warn surviving family members 
of their possible risk for SCD events in the future.   
There are many genes that may contribute to elevated risk of SCD events.  
Commercial vendors of DNA typing reagents market next generation DNA sequencing 
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kits that interrogate SNP sites in hundreds of genes simultaneously (Illumina, Inc., San 
Diego, CA; Applied Biosystems Inc., Carlsbad, CA; Qiagen Inc., Mansfield, MA).  
Interrogating a large panel of genes, while yielding a complete genetic picture of the 
constellation of SNPs present in the genome, may not result in a conclusive diagnosis of 
the underlying cause of SCD for a given victim because of the interplay of SNPs in 
numerous genes that collectively elevate risk.  Moreover, the use of next generation DNA 
sequencing, while providing in depth coverage of the genes potentially involved, is 
expensive and data management and storage are extensive.  Our strategy for investigating 
a possible correlation of SCD or other cardiac conditions leading to death with gene 
defects was to use a simple molecular assay interrogating 5 SNPs residing in 4 genes 
known to be associated with cardiac function.  The experimental plan was to screen 
genomic DNA isolated from blood samples from a cohort of individuals investigated for 
cause of death by the Medical Examiner as well as a group of presumably normal 
individuals.  The four genes chosen (EYA4, MYH6, TNNI3, and NEXN) have been 
found by other researchers to play a role in the normal functioning of cardiac muscle and 
SNPs residing within these genes have been implicated with dilated cardiomyopathy and 
hypertrophic cardiomyopathy.11  The five SNPs interrogated in our panel all result in 
nucleotide changes within the genes: the SNPs within EYA4 and NEXN all change a 
nucleotide within an untranslated region within the mRNA whereas the SNPs associated 
with EYA4-2, MYH6, and TNNI3 represent missense changes that alter the amino acid 
sequence of the protein.4  While an untranslated region may seem like it should have no 
consequence or protein function, enhancers are known to exist within the UTR and so it 
is possible gene expression effects could accompany SNPs residing within the UTR.  The 
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gene EYA4 has two SNP sites and variant alleles at both sites have been suggested by 
others to have pathogenic effects on gene function.19 The EYA4 gene has been associated 
with cardiac muscle function and some forms of the gene are associated with 
cardiomyopathies that cause impaired contracting of the ventricles in the heart.   
MYH6 was chosen for our panel due to its causation of premature deaths from 
cardiac failure due to dilated cardiomyopathies.  TNNI3 is a gene that encodes a protein 
in the heart called troponin I.  Troponin I regulates heart contractions and nucleotide 
sequence variations in TNNI3 has been found associated with many cardiomyopathies.  
Nucleotide sequence variations in the NEXN gene have been associated with hereditary 
dilated and hypertrophic cardiomyopathies that can cause the heart to collapse after 
intense exercise.20  Due to the genes’ associations with cardiomyopathies, the SNPs they 
possess are good candidates for exploring the association of SNPs with lethal defects in 
cardiac function.  The SNP’s have been named after the gene they are located in for 
convenience: the two EYA4 SNPs are EYA4 and EYA4-2, MYH6’s SNP is MYH6, 
TNNI3’s SNP is TNNI3, and NEXN’s SNP is NEXN.  These genes and their nucleotide 
sequence variants were chosen for our studies due to published work by Millat et al 
(2014) Brion et al. (2015) and from previous next generation DNA sequencing performed 
at OSU by Dr. Shen Di.  In her work, a limited number of bloodstain samples were 
obtained from the Oklahoma Office of the Chief Medical Examiner and the DNA 
extracted from the stains was subjected to massively parallel DNA sequencing (MPS).  
The library used in MPS consisted of 58 genes associated with SCD.  The SNPs in 
NEXN, EYA4, and TNNI3 were all chosen from this study and then the possible role of 





The results of our genotyping produced 112 alleles (56 individuals) for each of 
the SNP sites from the normal population group and 56 alleles (28 individuals) for each 
of the SNP sites from the Medical Examiner (ME) population group.  Analysis of the data 
began with a simple analysis of whether there were more pathogenic variants at the SNP 
sites in the ME group when compared with the normal group.  Results from that analysis 
showed that indeed the ME population group harbored more pathogenic SNPs overall 
than did the normal group although pathogenic alleles did exist in the normal population 
group.  Given the frequency of the wild type and variant SNPs for all genes (except 
MYH6), it appears these SNPs represent di-alleles rather than mutations.  Thus, SNP- 
alleles for each site were counted in the normal population to establish an allele 
frequency database.  It should be noted here that although most SNPs exhibited 
characteristics of di-allelic genetic markers (because the frequencies of the alternate 
nucleotide forms of the SNP exceeded by 1% by a large margin), the SNP associated with 
MYH6 exhibited characteristics more akin to a mutation in that only a single SNP variant 
was found in the MYH6 gene in an ME sample and no variants were found in the normal 
population group.  We also performed population genetic analysis of the genotyping 
results and found that each SNP-gene was in equilibrium within both the normal and ME 
population groups.  The EYA4-2 SNP was close to not being in equilibrium and perhaps 
if the number of ME samples was higher, an association of EYA4-2 with cardiac death 
might have been revealed (Table 12). 
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The differences in overall frequency of wild type and pathogenic nucleotides at 
the individual SNP sites in the normal samples and in the medical examiner samples were 
evaluated statistically using a contingency table.  The difference in frequency of wild 
type and pathogenic alleles is significant considering all SNPs as a whole (p <0.0001).  
Thus, the frequency of pathogenic alleles is significantly higher in the ME group than the 
normal group.  Moreover, within each population group, the frequencies of wild type and 
pathogenic alleles at the EYA4 and EYA4-2 loci are NOT significantly different from 
each other.  This might be expected since both SNPs are found in the same gene.  NEXN, 
TNNI3, and MYH6 are also seen as NOT significantly different from each other as 
denoted by the letter “b”.  While NEXN and TNNI3 are not different from each other, 
they are significantly different from EYA4 and EYA4-2.  Within the normal population 
group, wild type and pathogenic SNPs at EYA4 and EYA4-2 are also NOT significantly 
different in the normal sample group, as was the case for the ME sample group.  
However, the EYA4 SNPs are significantly different from all other SNPs.  MYH6 and 
TNNI3 are this time seen as NOT significantly different from each other and, but NEXN 
is significantly different from all other SNPs.  With the exception of NEXN, pathogenic 
alleles were more common in the ME sample group. 
Given the heterogeneous causes of SCD, it was also important to ask whether 
particular combinations of nucleotide variants in different genes were significantly 
different in the ME and normal population groups.  To address this question, we 
performed analyses of SNP genotypes from pairs of genes in the two population groups, 
asking whether the expected and observed frequencies at two SNP sites were 
significantly different.  If two genetic markers are in population equilibrium, it is possible 
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to use the population genetic theory to predict the frequency of genotypes for each 
marker, given the allele frequencies. If two genetic markers are in linkage equilibrium, it 
is possible to multiply each genotype frequency by the other to produce the frequency of 
a pair of genotypes that can be found in a given individual within the population.  If 
combinations of pathogenic SNPs are “linked” or significantly “correlated” with cardiac 
function anomalies that led to the death of members of the ME population group, we 
would expect the observed genotypes to vary significantly from expectations.  When this 
experiment was performed we found that the observed pairwise comparisons of SNPs did 
not differ significantly from expectations in the normal population group, but did differ 
significantly in the ME population group.  These results support the general consensus of 
opinion that cardiac disease, and especially cardiac disease leading to unexpected death, 
results from the interplay of more than one SNP.  Among the pairwise comparisons p-
values ranged over multiple orders of magnitude suggesting some SNP combinations 
could be more significant in elevating risk for cardiac risk than others.  
 
Limitations of the Study 
 There are several limitations in our study.  One key limitation is the size, age, and 
type of the group of samples that were tested.  Large control samples are often used to 
make comparisons to results produced from an affected group.  While a large number of 
control and SCD samples would have been extremely helpful and possibly strengthened 
our conclusions, it was difficult to obtain large numbers of samples from victims known 
to have died from SCD.  SCD is difficult to diagnose and until a compelling diagnostic 
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test is widely available, collecting a large cohort of affected DNA samples will be 
difficult.  Studies performed by Skinner et al. and Brion et al. focused on young sudden 
unexplained deaths (SUD) rather than expanding their number of samples to include 
deaths resulting for all cardiac causes.  While a definitive diagnosis for SCD will likely 
await extensive DNA analysis using some of the new technologies available today, 
interpretation of the massive amount of data produced and the high frequency of SNP 
variations in human genomic DNA, deciphering the SNPs that are causative of SCD from 
those that are not associated with SCD represents a complex challenge that will take time.   
Many studies (including Brion et al. 2015) use large gene-panels to investigate 
possible genetic causes of SCD. However, as our results showed, presumably pathogenic 
alleles can be detected in unaffected individuals who have advanced in age beyond that 
considered at an elevated risk for SCD.  Therefore, even massively parallel DNA 
sequencing faces challenges in designing a compelling diagnostic molecular assay that is 
effective for the diagnosis of SCD.  In contrast, a simple molecular assay, while perhaps 
missing gene defects that could result in a diagnosis of SCD nonetheless was effective in 
a limited population of victims of cardiac related death of identifying pathogenic SNPs 
that were highly correlated with defects in cardiac function that could have explained the 
death.  It would be easily possible to expand the number of SNPs subjected to SNaPshot 






Conclusions and Possible Future Studies  
  SNP polymorphisms occur within the human genome with a frequency of about 1 
per 500-1000 nucleotides of genomic sequence.  Hence variations in nucleotide sequence 
are common both in genes and between genes and yet have no apparent effect on survival 
and normal life.  The results of our study would be enhanced by increasing the size of the 
two population groups used as a source of DNA for study.  In addition, the sensitivity of 
our approach-using SNaPshot for the diagnosis of SCD-would be improved if additional 
SNPs in other genes associated with cardiac function were included in our limited gene 
panel.  While sequencing large panels composed of hundreds of genes could be the most 
informative for diagnosing SCD, it seems there needs to be more of a consensus on the 
criteria that define SCD and there will need to be bioinformatics solutions to analyzing 
the massive amount of DNA sequence produced with this approach. Our results suggest 
that a more limited approach using simpler molecular technology that could be used by 
the medical examiner would improve their ability to identify cause and manner of death 
for those victims whose autopsy results do not identify the cause of death.  If pathogenic 
alleles are identified in a decedent, the ME could then alert surviving family members to 
follow up with their own healthcare providers to help ensure their continued health in the 
future.  And, if molecular analysis could be conducted on those who are at significant risk 
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